Infinium Pharmachem Ltd. · NSE:INFINIUM
Infinium Pharmachem — Investor Presentation (June 2024)
38 slides from Infinium Pharmachem's investor presentation, Jun 9, 2024
Slide 1: Cover letter to NSE for analyst meeting
9th June, 2024 To, The Listing Department National Stock Exchange of India Limited Exchange Plaza, C-1, G Block Bandra Kurla Complex, Mumbai – 400 051 NSE Symbol: INFINIUM Sub:: - Presentation for Analysts/Institutional Investors Meeting Dear Sir / Madam, Pursuant to Regulation 30 read with Schedule
Slide 2: Infinium Pharmachem Limited Investor Presentation June 2024
INFINIUM PHARMACHEM LIMITED INVESTOR PRESENTATION JUNE 2024 1
Slide 3: Safe Harbour
Safe Harbour The presentation has been prepared by Infinium PharmaChem Limited (the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall form th
Slide 4: Table of Content
Table of Content Page No. 1. Business Overview 4-5 2. Strategic Updates & Key Highlights 6 3. Rationale for the Deal 7 4. Group Companies 8-13 5. Investment Thesis 14-25 6. Financial Overview 26-30 7. Annexure 31-37 3
Slide 5: Business at a Glance
Business at a Glance Incorporated in 2003 at Anand, Gujarat. Manufacturing high-quality Iodine Derivatives & APIs. Catering majorly to pharmaceutical Industry. Works on CRAMS model. 5-years Revenue CAGR of 36.71%. EBITDA margin expanded approx. 2x in last 5-years. Consistent Gross margin of 22-29% o
Slide 6: Our capabilities
Our capabilities • Iodine is a nonmetallic element and cannot be produced using chemical synthesis, from an industry standpoint it can be only extracted as iodine containing resources. The global iodine market share is divided by source, form, application and region. At Infinium PharmaChem Ltd Manuf
Slide 7: Strategic Updates & Key Highlights
Strategic Updates & Key Highlights The company has considered and approve investment in Infinium Healthcare Private 1 Limited, making it a subsidiary company. The company has presented for its members approval issue of 19,56,000 fully 2 convertible warrants on preferential basis aggregating upto Rs
Slide 8: Rationale For The Deal
Rationale For The Deal Fund Raise Details • Issue of 19,56,000 fully convertible warrants, aggregating upto Rs 44,50,68,240. • Issue Price of Warrant Rs 227.54/- per warrant. Details • The offer was to non-promoter investors. • Subject to necessary approvals, within 15 days from the date of passing
Slide 9: Infinium Healthcare Private Limited
Infinium Healthcare Private Limited Iodine is a precious element on earth and is rarely available. Extracting it is difficult depending upon on the source and the method. Infinium Group overcame this barrier by strategically entering in joint venture viz. IBL Elements Inc. (A Texas Corporation, USA)
Slide 10: Iodine Extraction- Our approach to the problem
Iodine Extraction- Our approach to the problem What does IBL Elements do: USP of the Project: • Extracts iodine from saltwater collected during oil and gas • Present value ~ USD 2.2 Mn & have tapped the extraction. opportunity of Iodine extraction in USA. • Assured market of IBL product considering
Slide 11: Group Companies - Pre-Acquisition
Group Companies Pre-Acquisition Infinium Group Infinium PharmaChem Infinium Healthcare Private Limited Limited Infinium Green Energy Private Limited Shanghai Tajilin Industrial Co. Limited No Holding of Infinium PharmaChem Limited. Only Common directors. Infinium PharmaChem Limited holds 51% Infiniu
Slide 12: Group Companies - Post Acquisition
Group Companies Post Acquisition Infinium Group Infinium PharmaChem Limited Infinium Green Energy Private Limited Shanghai Tajilin Industrial Co. Limited Infinium Healthcare Private Limited Infinium PharmaChem Limited holds 51% Infinium PharmaChem Limited holds 51% Infinium PharmaChem Limited holds
Slide 13: Shanghai Tajilin Industrial Co. Limited
Shanghai Tajilin Industrial Co. Limited % of holding Established in March 2019, Shanghai Tajilin Industrial Co.,Ltd is a Joint venture agreement entered between Infinum Pharmachem Limited and Shanghai Witofly Chemical Co. Ltd. Incorporated in China for exclusive distributorship in China Market for I
Slide 14: Infinium Green Energy Private Limited
Infinium Green Energy Private Limited Located in Dhutapur (Ramnagar), Jamnagar Gujarat. Infinium Green Energy Private Limited is Bio coal manufacturer that deals in Bio Coal, Bio Gas, Bio Energy, agro waste briquettes, white coal and Biomass Briquettes and other products related to renewable energy
Slide 15: Investment Thesis
Investment Thesis Beyond geographies Backward Integration Expertise in R&D o Expanding reach to over 20+ o Well established relations with o Product portfolio of 200+ Iodine countries globally material suppliers Derivatives o Significantly increasing customer base o Navigate many supply chain o Manu
Slide 16: Business Model
Business Model The Company is dealing specifically and mainly in manufacturing and supplying of Iodine Derivatives, Pharma Intermediates and Active Pharmaceutical Ingredients (APIs). The Company undertakes Contract Research and Manufacturing Services (CRAMS) to provide customized and fully confident
Slide 17: Stable Market Scope Across Asia
Stable Market Scope Across Asia Standalone Revenue (In INR Crore) 15 10 16 1 20 12 2 12 4 3 8 90 0 70 12 0 3 42 48 21 FY 20 FY 21 FY 22 FY 23 FY 24 India Japan China Others • Company has strong growth in emerging market business while focusing on multiple Industries. • It is very aggressive in promo
Slide 18: Revenue and Customers
Revenue and Customers Segment-wise Revenue Contribution (Standalone INR Crores) 332 274 286 292 122 101 239 74 55 36 FY 20 FY 21 FY 22 FY 23 FY 24 Total No. Of Customers 17
Slide 19: Raw Material Procurement
Raw Material Procurement Segment wise Procurement (Standalone INR Crores) FY 20 FY 21 FY 22 FY 23 FY 24 6 9 26 22 30 44 37 32 73 25 Iodine Other Chemicals Iodine Other Chemicals Iodine Other Chemicals Iodine Other Chemicals Iodine Other Chemicals Raw materials used: Iodine and Other Chemicals viz Ca
Slide 20: Consistently Creating Milestones Over Time
Consistently Creating Milestones Over Time 2019: Expanded to 2021: Crossed Rs. 50 2021: Augmentation of 2022: Focused on 2023: Listed on 15+ countries. crores revenue. production capacity. backward integration. NSE. 136 114 99 71 39 FY 20 FY 21 FY 22 FY 23 FY 24 Consolidated Revenue (in INR Crore) 1
Slide 21: Fast Growth Trajectory
Fast Growth Trajectory EBITDA CAGR 60.05% PAT CAGR 90.89% 15% 8% 8% 15% 12 20 7% 11% 17 10 8% 8% 7 11 4% 2% 6 3 3 1 FY 20 FY 21 FY 22 FY 23 FY 24 FY 20 FY 21 FY 22 FY 23 FY 24 Consolidated EBITDA (in INR Crores) EBITDA Margin PAT (in INR Crores) PAT Margin *Note: EBITDA is consolidated Revenue from
Slide 22: Capex for Expansion
Capex for Expansion Expansion plans: • Expansion of current facilities • Extending facilities for Contrast Media intermediate that will be used in PET scan, MRI, X-ray etc. Particulars Planned Incurred Date of completion Expansion 21.92 Crores 15 Crores 31 July 2024 Project of current facilities Exp
Slide 23: Strategic Positioning & Growth Outlook
Strategic Positioning & Growth Outlook • Established Iodine derivative manufacturer with niche expertise in landing tough Chemicals. • Moving up the Value chain • Launching new product in FY 2026 • REACH registration is recognized for marketing in EU. • EU-REACH Registration under consideration for
Slide 24: Quality & Regulatory Compliances
Quality & Regulatory Compliances ISO 22000:2005 focus Ranging from early- on Food Safety stage development to WHO- GMP Compliant document control and Management systems Manufacturing Plant pilot scale validation ISO 14001:2015 focus & Production. to bulk scale on environmental ISO 9001-2015 Certifie
Slide 25: Industry Insights- Global Outlook
Industry Insights- Global Outlook Global Iodine Market Global Pharmaceutical Market Global API Market Expected CAGR: 4.95% (2022-30) Expected CAGR: 12.5% (2020-27) Expected CAGR: 6.52% (2022-27) Global Iodine Market (In $ Mn) Global Pharmaceutical Industry (In $ Bn) Global API market (In $ Bn) 970.5
Slide 26: Industry Insights- India Outlook
Industry Insights- India Outlook Indian Pharmaceutical Industry Indian API Market Expected CAGR: 15% (2024-32) Expected CAGR: 8.3% (2021-28) Indian Pharmaceutical Industry (In $ Bn) Indian API market (In $ Bn) 163.1 34.97 19.99 54.6 2024 2032 2021 2028 Source: https://www.imarcgroup.com/india-pharma
Slide 27: Financial Overview
FINANCIAL OVERVIEW 26
Slide 28: Consolidated Profit & Loss Statement Highlight
Consolidated Profit & Loss Statement Highlight Particulars (in INR Crore) H2FY24 FY24 FY23 YoY Revenue from Operations 74.18 135.66 114.22 19% Other Income 1.20 1.54 1.35 14% Cost of Goods Sold 58.39 103.10 80.57 28% Gross Profit 15.79 32.55 33.65 -3% Gross Profit Margin (% of Revenue from 21.28% 24
Slide 29: Consolidated Profit & Loss Statement Summary
Consolidated Profit & Loss Statement Summary (In INR Crore) Particulars FY 20 FY 21 FY 22 FY 23 FY24 Revenue from Operations 38.84 70.53 99.12 114.22 135.66 Other Income 0.57 0.62 0.93 1.35 1.54 Cost of Goods Sold 30.14 54.86 76.74 80.57 103.10 Gross Profit 8.70 15.67 22.38 33.65 32.55 Gross Profit
Slide 30: Consolidated Balance Sheet Summary
Consolidated Balance Sheet Summary (In INR Crore) Equity and Liabilities FY 20 FY 21 FY 22 FY 23 FY 24 Assets FY 20 FY 21 FY 22 FY 23 FY 24 Equity Share Capital 1.02 1.02 1.02 5.08 13.92 Non- Current Assets Other Equity 3.23 6.01 12.09 17.48 44.86 Property, plant and 4.15 4.72 4.20 18.81 19.64 Non c
Slide 31: Consolidated Cash Flow Statement Summary
Consolidated Cash Flow Statement Summary (In INR Crore) Particulars FY 20 FY 21 FY 22 FY 23 FY 24 Cash from Operations 3.03 7.29 11.79 8.55 -13.04 Cash from Investing (1.05) (4.99) (6.63) (4.95) -3.79 Cash from Financing (1.24) (1.16) (1.70) (3.10) 22.77 Net (Decrease)/Increase in cash 0.74 1.13 3.4
Slide 32: Annexure
ANNEXURE 31
Slide 33: Vision And Mission
Vision And Mission Vision To be a globally integrated & admired Pharmaceutical & Healthcare company Mission To research, develop & successfully market extremely customized Pharmaceuticals & Healthcare products & services while strictly adopting the highest level of: Effectiveness & Efficiencies
Slide 34: Creating Products, Improving Health
Creating Products, Improving Health Key Iodine derivatives Featured API • Dess Martin Periodine • Potassium Iodide (IP, BP,USP,JP,EP,ACS)- Used for • Iodobenzene treating hyperthyroidism. • N- Iodosuceinamide • Pralidoxime Iodide- Antidote and cholinesterase • Lithium Iodide Hydrate • Tetrabutyl-amm
Slide 35: Marquee Clientele
Marquee Clientele Industries served Companies served Pharmaceuticals Chemical Cosmetics Bio-Tech Nutraceutical Electronics Solar Paints/ Coatings Animal Feed Textiles 34
Slide 36: Board Of Directors
Board Of Directors SANJAYKUMAR VITHTHALBHAI PATEL PRAVIN BADHABHAI MADHANI MITESH LAVJIBHAI CHIKHALIYA Promoter and Managing director Promoter and Director Promoter and Director He holds a master degree from Gujarat He is a postgraduate and hold LLB He holds a master degree from Savitribai Universit
Slide 37: Board Of Directors
Board Of Directors KEYUR JAGDISHCHANDRA SHAH TARUN RATILAL DOBARIYA VAISHAKHI AMBRISHBHAI SHUKLA Independent Director Independent Director Independent Director He is a Company Secretary, MBA in With technical know-how in Non- She holds master degree and Graduate Finance and a practicing Insolvency F
Slide 38: Infinium Pharmachem Limited contact details
Infinium Pharmachem Limited Suite #205, "SIGMA PRIME", Second Floor, Nr. Sardar Patel Statue, V.U. Nagar GIDC Road, Vallabh Vidyanagar – 388120, Gujarat, INDIA Phone: +91-2692-238849 / 238850 Email: info@infiniumpharmachem.com Website: https://infiniumpharmachem.com/ Investor Relations Go India Advi
Infinium Pharmachem — Investor Presentation (June 2024) on 6ix